Conclusions
tixagevimab-cilgavimab
SARS-COV-2 INFECTION
Results of these 2 randomized clinical trials indicate that tixagevimab-cilgavimab administered IM to the thigh was safe but neither IM nor IV treatment had significant effects on measured symptom outcomes. An antiviral effect of tixagevimab-cilgavimab was demonstrated in the primary virologic analysis for IM and other analyses in the truncated IV study. There were numerically fewer hospitalizations with receipt of tixagevimab-cilgavimab.Therapeutic options for COVID-19 remain limited. At present, there are no mAbs available with activity against the circulating SARS-CoV-2 variants. Our findings support IM thigh administration of mAbs, a route that should be considered in development of mAbs for SARS-CoV-2 infection.